Branch retinal vein occlusion: Natural history of visual outcome

JAMA Ophthalmology

Volumn 132, Issue 1, 2014, Pages 13-22

  Hayreh, Sohan Singh ^a,c   Zimmerman, M Bridget ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMSLER CHART; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EYE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANUAL PERIMETER; MIDDLE AGED; OBSERVATIONAL STUDY; PERIMETRY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULA EDEMA; VISION; VISUAL ACUITY; VISUAL ACUITY CHART; VISUAL FIELD; VISUAL FIELD DEFECT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MACULAR EDEMA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RETINAL VEIN; RETINAL VEIN OCCLUSION; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84892775596     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.5515     Document Type: Article

References (38)

1. Oeller J. Atlas der Ophthalmoskopie Wiesbaden. C. Tabs XIII. 1896-1899.
2. Moore RF. Retinal vein thrombosis: a clinical study of 62 cases followed over many years. Br J Ophthalmol. 1924;2(suppl):4-90.
3. Jensen VA. Clinical studies of tributary thrombosis in the central retinal vein. Acta Ophthalmol Suppl. 1936;10:55-61.
4. Hill DW, Griffiths JD. The prognosis in retinal vein thrombosis. Trans Ophthalmol Soc U K. 1970;90:309-322.
5. Michels RG, Gass JDM. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2):OP166-OP177.
6. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2):OP178-OP192.
7. Clemett RS, Kohner EM, Hamilton AM. The visual prognosis in retinal branch vein occlusion. Trans Ophthalmol Soc U K. 1973;93(0):523-535.
8. Yano S, Kamei M, Suzuki M, Nishida K. Prognosis for branch retinal vein occlusion [in Japanese]. Nihon Ganka Gakkai Zasshi. 2011;115(12):1073-1078.
9. Clements DB, Elsby JM, Smith WD. Retinal vein occlusion: a comparative study of factors affecting the prognosis, including a therapeutic trial of Atromid S in this condition. Br J Ophthalmol. 1968;52(2):111-116.
10. Shilling JS, Jones CA. Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol. 1984;68(3):196-198. (Pubitemid 15134727)
11. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-282.
12. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol. 1986;104(1):34-41.
13. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol. 1994;118(4):421-429. (Pubitemid 24307208)
14. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
15. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112, e1.
16. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041- 2049.
17. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-809.
18. Varma R, Bressler NM, Suñer I, et al; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10): 2108-2118.
19. Scott IU, Vanveldhuisen PC, Oden NL, et al; SCORE Study Investigator Group. Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study: SCORE Study report 14. Arch Ophthalmol. 2012;130(12):1517-1524.
20. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101, e5.
21. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion, III: incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488-506. (Pubitemid 13059778)
22. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429-441. (Pubitemid 24115701)
23. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(1):119-133, e1-e2.
24. Hayreh SS, Zimmerman MB. Hemicentral retinal vein occlusion: natural history of visual outcome. Retina. 2012;32(1):68-76.
25. Finkelstein D. Ischemic macular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol. 1992;110(10): 1427-1434.
26. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81-87. (Pubitemid 350167096)
27. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;31(8):1449- 1469.
28. Semeraro F, Morescalchi F, Parmeggiani F, Arcidiacono B, Costagliola C. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol. 2011;9(5):629-646.
29. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-2034.
30. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2): 266-272.
31. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012;43(4):328-334.
32. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111-1114.
33. Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012;11(2): 331-340.
34. Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115(2):298-305, e2.
35. Hayreh SS, Zimmerman B. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Arch Ophthalmol. 2005;123(11): 1554-1562. (Pubitemid 41626692)
36. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493-519. (Pubitemid 40544632)
37. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122(3):330-335. (Pubitemid 38314192)
38. Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion: retinal survival time. Exp Eye Res. 2004;78(3):723-736. (Pubitemid 38183351)